Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · GeoVax Labs, Inc. (GOVX)

GeoVax Labs names Tyler O'Brien interim CEO and chairman; adds director Shahin Behroyan

Neutral Impact 4 of 5 leadership

GeoVax Labs appointed Tyler O'Brien as interim Chief Executive Officer and Chairman of the Board effective November 8, 2026, and added Shahin Behroyan as a director effective November 5, 2026. The filing follows the resignation of five former directors effective October 23, 2026, and it references a dispute over the termination of a former executive, Mr. Dodd, for Cause, which the company says could lead to severance or litigation. Shareholders face a leadership change at the top of the company while a permanent CEO is sought.

Key points

  • Tyler O'Brien appointed interim CEO and Chairman of the Board effective November 8, 2026; will serve until a permanent principal executive officer is appointed or designated
  • Shahin Behroyan appointed to the Board effective November 5, 2026, to fill a vacancy from the resignation of five former directors effective October 23, 2026
  • Behroyan is not yet on any committee; Board determined he is independent under Nasdaq Rule 5605(a)(2)
  • Forward-looking statements cite a possible dispute with Mr. Dodd over termination for Cause, with potential severance of three times base salary and target bonus

The filing

CompanyGeoVax Labs, Inc. (GOVX)
Form8-K, current report
Filed with the SECNov 9, 2026, 4:32 PM ET
Accession number0001437749-26-035911

Items reported: 5.02 Director / Officer Change

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 4:46 PM ET, from this filing only.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.